Coya Therapeutics promising interim results from dementia study

 

• Coya Therapeutics (NASDAQ:COYA) reported positive interim results from an open-label study testing a combination of low-dose IL-2 and CTLA4-Ig for the treatment of frontotemporal dementia.
• In the interim results of the first five patients, the treatment led to a significant and lasting boost in both the number and function of regulatory T cells (Tregs), compared to their starting levels.
• The company said that patients showed little to no decline in cognitive function during the study.
• When it came to safety, the therapy was also well tolerated, with no serious side effects, and all five patients completed the study.

https://www.msn.com/en-us/health/other/coya-therapeutics-reports-promising-interim-results-from-dementia-study/ar-AA1DxKqt